MediWound (NASDAQ:MDWD) Issues Earnings Results, Misses Estimates By $0.01 EPS

MediWound (NASDAQ:MDWD) issued its earnings results on Thursday. The biopharmaceutical company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.01), Zacks reports. The firm had revenue of $3.09 million for the quarter, compared to analyst estimates of $2.59 million. MediWound had a negative return on equity of 67.22% and a negative net margin of 180.30%.

Here are the key takeaways from MediWound’s conference call:

• EscharEx’s VALUE Phase III trial remains on track, with interim sample-size reassessment and enrollment completion targeted by the end of Q1 2027. The company says nearly all of the approximately 40 sites are recruiting.
• MediWound expanded its estimated U.S. peak annual sales opportunity for EscharEx to $1.05 billion after including pressure ulcers, and plans to start a 50-patient diabetic foot ulcer study and a small pressure-ulcer investigator-initiated study in Q4 2026.
• NexoBrid’s U.S. commercial adoption continued to improve, with Vericel reporting record quarterly revenue, hospital unit sales and ordering centers; approximately 80 U.S. burn centers have ordered the product since launch.
• The new master service agreement with Vericel is expected to begin contributing revenue in the second half of 2026, including development programs targeting blast and friction injuries. MediWound reaffirmed 2026 revenue guidance of $24 million–$26 million, weighted heavily toward the second half.
• Financial performance weakened in the first half: Q2 revenue fell to $3.1 million from $5.7 million year over year, while cash and deposits declined to approximately $36 million from $54 million at year-end 2025 after $20 million of first-half cash burn. R&D spending is expected to remain elevated as the VALUE trial advances, and expanded-facility commercial supply is not expected until the second half of 2027.

MediWound Trading Down 2.7%

MDWD stock traded down $0.38 during trading on Thursday, hitting $13.53. The company had a trading volume of 62,264 shares, compared to its average volume of 63,044. MediWound has a one year low of $13.46 and a one year high of $20.30. The stock has a market cap of $173.86 million, a PE ratio of -5.99 and a beta of 0.15. The business has a 50-day moving average of $14.36 and a 200-day moving average of $15.99.

Analysts Set New Price Targets

MDWD has been the topic of several research analyst reports. Oppenheimer reissued an “outperform” rating and issued a $32.00 price target (down from $33.00) on shares of MediWound in a report on Wednesday, May 27th. HC Wainwright reiterated a “buy” rating and set a $36.00 target price on shares of MediWound in a research note on Thursday, May 28th. Wall Street Zen raised MediWound from a “strong sell” rating to a “sell” rating in a report on Saturday, May 30th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MediWound in a report on Friday, July 17th. Two research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and an average price target of $34.00.

Insiders Place Their Bets

In other news, Director David Morton Fox acquired 3,537 shares of the firm’s stock in a transaction on Monday, June 1st. The stock was purchased at an average price of $14.11 per share, for a total transaction of $49,907.07. Following the purchase, the director owned 22,283 shares in the company, valued at approximately $314,413.13. This represents a 18.87% increase in their position. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Company insiders own 9.20% of the company’s stock.

Institutional Trading of MediWound

A number of institutional investors have recently modified their holdings of MDWD. Quarry LP bought a new position in shares of MediWound in the fourth quarter worth $26,000. BNP Paribas Financial Markets increased its position in shares of MediWound by 90.4% during the third quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock valued at $27,000 after buying an additional 723 shares during the period. Russell Investments Group Ltd. increased its position in shares of MediWound by 69.1% during the second quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 649 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of MediWound by 22.4% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after buying an additional 999 shares in the last quarter. Finally, MetLife Investment Management LLC bought a new position in shares of MediWound in the fourth quarter valued at approximately $109,000. 46.83% of the stock is currently owned by hedge funds and other institutional investors.

About MediWound

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.